

Study Number: C12007-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

Study Number:

Study Sex:

PWG Approval Date:

Version:

PA41: Clinical Chemistry Summary

Test Compound: 2-(2H-benzotriazol-2-yl)-4,6-bis(1-methyl-1-phenylethyl)phenol)

CAS Number: 70321-86-7

C12007-01

Male

See web page for date of PWG Approval

v1.2.0

Date Report Requested: 05/19/2021

Time Report Requested: 05:54:46

Lab: Battelle

Study Number: C12007-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 2-(2H-benzotriazol-2-yl)-4,6-bis(1-methyl-1-phenylethyl)phenol

CAS Number: 70321-86-7

Date Report Requested: 05/19/2021

Time Report Requested: 05:54:46

Lab: Battelle

Male						
	Phase Day	Treatment Groups (mg/kg)				
		0	30	100	300	1000
Urea Nitrogen (mg/dL)	SD 14	15.6 ± 0.8 (5)	16.0 ± 0.3 (5)	15.4 ± 0.5 (5)	15.0 ± 0.5 (5)	15.8 ± 0.6 (5)
Percent of Control			102.6	98.7	96.2	101.3
Creatinine (mg/dL)	SD 14	0.36 ± 0.02 (5)	0.36 ± 0.02 (5)	0.36 ± 0.02 (5)	0.32 ± 0.02 (5)	0.32 ± 0.02 (5)
Percent of Control			100.0	100.0	88.9	88.9
Glucose (mg/dL)	SD 14	133.8 ± 1.9 (5)	132.8 ± 1.5 (5)	140.4 ± 4.2 (5)	157.0 ± 9.9 (5)	129.0 ± 3.8 (5)
Percent of Control			99.3	104.9	117.3	96.4
Total Protein (g/dL)	SD 14	6.58 ± 0.08 (5)	6.94 ± 0.08 (5) *	6.86 ± 0.07 (5)	6.58 ± 0.10 (5)	6.68 ± 0.11 (5)
Percent of Control			105.5	104.3	100.0	101.5
Globulin (g/dL)	SD 14	2.22 ± 0.07 (5)	2.46 ± 0.05 (5) *	2.36 ± 0.04 (5)	2.28 ± 0.02 (5)	2.30 ± 0.05 (5)
Percent of Control			110.8	106.3	102.7	103.6
A/G Ratio	SD 14	1.97 ± 0.06 (5)	1.82 ± 0.03 (5)	1.91 ± 0.03 (5)	1.89 ± 0.03 (5)	1.91 ± 0.03 (5)
Percent of Control			92.5	96.9	95.7	96.8
Albumin (g/dL)	SD 14	4.36 ± 0.02 (5)	4.48 ± 0.04 (5)	4.50 ± 0.04 (5)	4.30 ± 0.08 (5)	4.38 ± 0.07 (5)
Percent of Control			102.8	103.2	98.6	100.5
Cholesterol (mg/dL)	SD 14	127.8 ± 4.2 (5) **	118.8 ± 3.6 (5)	121.8 ± 6.4 (5)	109.6 ± 6.2 (5) *	111.4 ± 3.1 (5) *
Percent of Control			93.0	95.3	85.8	87.2
Triglyceride (mg/dL)	SD 14	120.2 ± 4.5 (5)	141.4 ± 12.3 (5)	139.8 ± 16.1 (5)	109.8 ± 6.1 (5)	103.0 ± 10.3 (5)
Percent of Control			117.6	116.3	91.3	85.7
Alanine Aminotransferase (IU/L)	SD 14	53.6 ± 1.1 (5)	55.6 ± 2.5 (5)	49.2 ± 1.9 (5)	54.2 ± 4.7 (5)	57.6 ± 4.1 (5)
Percent of Control			103.7	91.8	101.1	107.5
Alkaline Phosphatase (IU/L)	SD 14	189.0 ± 6.1 (5)	203.4 ± 13.8 (5)	177.2 ± 13.3 (5)	184.0 ± 11.0 (5)	194.0 ± 12.6 (5)
Percent of Control			107.6	93.8	97.4	102.6

Study Number: C12007-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 2-(2H-benzotriazol-2-yl)-4,6-bis(1-methyl-1-phenylethyl)phenol)

CAS Number: 70321-86-7

Date Report Requested: 05/19/2021

Time Report Requested: 05:54:46

Lab: Battelle

Male

		Treatment Groups (mg/kg)									
Phase Day		0		30		100		300		1000	
Creatine Kinase (IU/L) Percent of Control	SD 14	141.6 ± 11.9 (5)		234.0 ± 43.6 (5)		211.2 ± 23.0 (5)		156.2 ± 32.6 (5)		166.6 ± 13.9 (5)	
				165.3		149.2		110.3		117.7	
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 14	7.1 ± 0.2 (5)		7.5 ± 0.3 (5)		8.3 ± 0.6 (5)		8.0 ± 0.6 (5)		8.1 ± 0.4 (5)	
				106.2		116.9		112.7		114.1	
Bile salt/acids (umol/L) Percent of Control	SD 14	16.2 ± 4.6 (5)		12.2 ± 3.0 (5)		16.4 ± 3.8 (5)		15.0 ± 3.8 (5)		30.6 ± 6.2 (5)	
				75.3		101.2		92.6		188.9	

Study Number: C12007-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 2-(2H-benzotriazol-2-yl)-4,6-bis(1-methyl-1-phenylethyl)phenol)

CAS Number: 70321-86-7

Date Report Requested: 05/19/2021

Time Report Requested: 05:54:46

Lab: Battelle

LEGEND

Values given as mean $\pm$ SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day

Statistical analysis were performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

**** END OF REPORT ****